Eupraxia Pharmaceuticals (EPRX) Receivables - Net (2023 - 2025)

Eupraxia Pharmaceuticals (EPRX) has reported Receivables - Net for 4 consecutive years, with $716095.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables - Net rose 177.48% year-over-year to $716095.0; the TTM figure through Dec 2025 stood at $716095.0 (up 177.48% YoY), while the FY2025 annual figure was $716095.0, up 177.48% from the prior year.
• Receivables - Net grew to $716095.0 in Q4 2025 per EPRX's latest filing, from $258074.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $716095.0 in Q4 2025 and bottomed at $13892.0 in Q4 2022.
• Historically, Receivables - Net has averaged $285452.5 across 4 years, with a median of $205911.5 in 2023.
• Annual changes were most pronounced in 2023 — Receivables - Net soared 1006.74% — and 2024, when it jumped 67.85%.
• Eupraxia Pharmaceuticals' Receivables - Net stood at $13892.0 in 2022, then jumped by 1006.74% to $153749.0 in 2023, then soared by 67.85% to $258074.0 in 2024, then jumped by 177.48% to $716095.0 in 2025.
• Business Quant data shows EPRX's Receivables - Net at $716095.0 in Q4 2025, $258074.0 in Q4 2024, and $153749.0 in Q4 2023.